Tag Archives: Johns Hopkins

June, 2017

1 June
Eisai and John Hopkins Extend Drug Discovery Collaboration with New Licensing Agreement

WOODCLIFF LAKE, N.J., May 31, 2017 /PRNewswire/ — Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., and Johns Hopkins University announced today that they have extended their drug discovery collaboration through an exclusive licensing agreement. The agreement is for a license of compounds identified from collaborative …
Share

15 May
Path to End HIV Could Be Within Reach for United States in Next Decade

The United States could be on track within the next decade to see significant steps towards ending the HIV epidemic in this country, suggests new research from the Johns Hopkins Bloomberg School of Public Health and Brigham and Women’s Hospital. The researchers say their findings reveal that, with adequate commitment, …
Share

11 November
Bristol-Myers and Johns Hopkins Collaborate on Immuno-Oncology Research

NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that the company has entered into a five-year research collaboration with the Johns Hopkins University. The collaboration is designed to identify mechanisms of response and resistance in patients whose cancer is being treated with checkpoint inhibitor-based immunotherapies, including Opdivo (nivolumab) monotherapy, or …
Share

3 August
‘Generic’ Biologic Drugs Appear Comparable to Brand-Name Counterparts

NEW ANALYSIS SUGGESTS COMMON AND COSTLY MEDICATIONS MADE FROM LIVING CELLS CAN BE EQUIVALENT EVEN WHEN MANUFACTURED BY DIFFERENT COMPANY Generic forms of a biologic drug used to treat rheumatoid arthritis, inflammatory bowel disease and psoriasis appear to be as safe and effective as their brand-name counterparts, a new Johns …
Share

16 October
Organ Transplant Drug Linked to Increased Risk of Rare Lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, called calcineurin inhibitors (CNIs), given alone or in …
Share